COMPANY:

OncoDNA

"OncoDNA...announced its participation in the oncNGS tender. Together with IQVIA, we are challenged by the ONCNGS CONSORTIUM to come up with a solution for analysis in liquid biopsies which should represent the ‘best NGS test, for all solid and lymphoid tumors’."

"OncoDNA...and ELI LILLY ITALIA...are proud to announce their partnership to facilitate access to biomarker testing and support the selection of the best therapy for thyroid cancer patients in italy...The partnership between Lilly and OncoDNA provides next-generation sequencing (NGS) molecular testing for thyroid cancer on tumor tissue biopsy to individuate treatable cancer biomarkers, by the identification of several gene alterations leading to potentially eligible patients for targeted therapies."

"...this is an important first step in a collaboration that will make it much easier for public and privately practising oncologists to access biopsy tissue and request ONCODEEP for the purpose of routine next generation sequencing."

"ONCODNA...ANNOUNCED THE OFFICIAL LAUNCH OF THE ONCODEEP KIT DURING THE ESMO (EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY) CONGRESS IN PARIS, FRANCE. THE KIT OFFERS A COMPLETE WORKFLOW SOLUTION TO ENABLE LABORATORIES WITH NGS CAPABILITIES TO SUPPORT ONCOLOGISTS IN FINDING THE MOST EFFECTIVE AND PERSONALIZED TREATMENTS FOR THEIR CANCER PATIENTS."

"OncoDNA...announced today a partnership with Synlab...integrating OncoDEEP in their portfolio, Synlab laboratories in Germany will perform comprehensive testing of solid tumors and deliver decision support for oncologists. The technology transfer is ongoing, with the objective of processing the first patient samples early Q2."

"OncoDNA...announced today the launch of the OncoDEEP kit. The kit offers a complete workflow solution which enables laboratories with NGS capabilities to perform comprehensive biomarker testing, provide powerful data analysis and support oncologists in the most effective and personalized treatments for their cancer patients. The OncoDEEP kit integrates both reagents and quality control standards for the sequencing of over 600 cancer biomarkers. the offer will come in combination with OncoDNA’s data analysis and clinical interpretation tools for the rapid analysis and reporting of a patient’s tumor molecular profile. OncoDEEP kit is available for early access and will be commercially available by the end of Q2 2022."

"C2i Genomics...announced expansion into Europe through a strategic partnership with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases. With entities based in Belgium, France, Spain and the UK, OncoDNA has built an outstanding network of cancer clinicians-researchers across Europe. The company will act as a primary lab partner, operating C2i’s whole-genome sequencing (WGS) and minimal-residual disease (MRD) cancer monitoring platform for European clinical research projects."

"OncoDNA...and Bergonié Institute...announced a new clinical trial to evaluate the use of comprehensive biomarker testing and liquid biopsy in 700 patients diagnosed with an advanced metastatic cancer. The Appolo study will recruit patients from 6 participating sites across the French Aquitaine region to be offered OncoDEEP® and OncoFOLLOW™ biomarker tests."

"OncoDNA...and SOPHiA GENETICS S.A....announced today an agreement facilitating the analysis and interpretation of genomic profiling...Under the terms of the agreement, OncoDNA will customize OncoKDM® – OncoDNA’s interpretation platform – to make it compatible with SOPHiA GENETICS’ AI-powered SOPHiA DDM™ platform. The combined offering will enable the analysis and automatic translation of complex genomic data obtained via SOPHiA DDM™ into actionable recommendations, empowering customers to generate tumor genomic profiling insights and produce individual reports."

"A new partnership between Rutherford Health plc...and OncoDNA...has been announced...The partnership will provide Rutherford cancer patients with access to the latest genomic testing developed by OncoDNA and support the accessibility and development of these tests within the UK...Comprehensive biomarker tests on solid and liquid biopsy help oncologists and cancer patients identify the most effective therapy for them, as well as monitor disease progression and therapeutic response."

"OncoDNA, Tamkin Al-Seha Medical and Bayer Saudi Arabia today announce a new partnership to facilitate access to tests for the neurotrophic tyrosine kinase (NTRK) gene biomarker (NTRK) and identify patients who may benefit from treatment by TRK inhibitor in the Kingdom of Saudi Arabia. During the preliminary phase of the collaboration, 1,000 patients with advanced metastatic tumors, all types of cancer, will be tested for potential fusions of the NTRK gene...The presence of the fusion in the tumor sample will be detected and confirmed by OncoDNA testing. These tests use next-generation sequencing (NGS) and immunohistochemistry (IHC) to identify biomarkers associated with cancer treatments."

"OncoDNA...and the Institut Jules Bordet...are pleased to announce their collaboration as part of an international, multicentre prospective interventional study aiming to better understand the biology of central nervous system (CNS) metastases. Sponsored by the Institut Jules Bordet within the Oncodistinct Network the BrainStorm study will enroll a total of 600 patients newly diagnosed with solid tumors in a dozen collaborating sites in France and Belgium and Luxembourg...As part of the BrainStorm study, OncoDNA will detect ctDNA in CSF samples using large next-generation sequencing panels as well as targeted gene panels on a selection of patient-specific mutations. The genomic data will be made available on a secured data interpretation platform that will help the Institut Jules Bordet to explore CNS metastases, and their heterogeneity with the primary solid tumor."

"A recent study 'Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations' published in the Journal of Clinical Oncology evaluated the efficacy of the farnesyltransferase inhibitor tipifarnib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) with HRAS mutations, a unique subset of the disease with high unmet needs. The study enrolled 30 patients with R/M HNSCC in a single-arm, open-label phase II trial of tipifarnib for mutant HRAS malignancies. Mutant HRAS status for enrollment was documented by local, approved gene-sequencing platforms; all patients submitted tissue from the most recent tumor biopsy for central laboratory confirmation and variant allele frequency (VAF) determination with OncoKDM, our NGS data interpretation platform."

"OncoDNA…announces the launch of a research project in collaboration with the Institut Curie...The objective of this project is to evaluate the effectiveness of liquid biopsy in the therapeutic monitoring of patients with head and neck cancer…Institut Curie and OncoDNA will analyze nearly 300 plasma samples in order to monitor the presence of tumor DNA circulating in the blood of patients. OncoFOLLOW ™ tests will be performed at different stages of treatment (surgery, radiotherapy or chemotherapy)."

"OncoDNA and myNEO said on Wednesday that they have partnered to develop personalized, mRNA-based vaccines to treat advanced cancer patients. Within the collaboration, the Belgium-based companies will use their respective technologies —OncoDNA's whole-genome and whole-transcriptome sequencing capabilities, and myNEO's artificial intelligence and bioinformatics capabilities — to identify targetable neoantigens in individual cancer patients and design mRNA-based vaccines that instruct their immune systems to go after those targets. Additionally, OncoDNA plans to use its blood-based next-generation sequencing test, OncoFOLLOW, to monitor patients' circulating tumor DNA after treatment with the bespoke vaccines." "